Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

SMB00958

Sigma-Aldrich

N-Desmethyl imatinib

≥95%

Synonym(s):

N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-(piperazin-1-ylmethyl)benzamide, N-Desmethylimatinib, N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)benzamide, CGP74588, Desmethyl Gleevec, Norimatinib

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C28H29N7O
CAS Number:
Molecular Weight:
479.58
UNSPSC Code:
12352205
NACRES:
NA.77

biological source

synthetic

Quality Level

grade

research grade

Assay

≥95%

form

solid

mol wt

479.58 g/mol

storage condition

(Tightly closed. Dry. Keep in a well -ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons.)

technique(s)

HPLC: suitable

solubility

ethanol: 0.20 mg/mL
DMF: 16 mg/mL

storage temp.

2-8°C

InChI

1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)

InChI key

BQQYXPHRXIZMDM-UHFFFAOYSA-N

General description

N-Desmethyl imatinib is a pharmacologically active metabolite of imatinib with long elimination half-life. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8.

Application

Application: Metabolomics research

Other Notes

For additional information on our range of Biochemicals, please complete this form.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SMB00958-5MG:
SMB00958-25MG:
SMB00958-VAR:
SMB00958-BULK:


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hans-Peter Gschwind et al.
Drug metabolism and disposition: the biological fate of chemicals, 33(10), 1503-1512 (2005-07-12)
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male
Muhammad Suleman Khan et al.
Xenobiotica; the fate of foreign compounds in biological systems, 46(3), 278-287 (2015-07-15)
1. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8. The effect of CYP2C8*3 genotype on N-desmethyl imatinib formation was unknown. 2. We examined imatinib N-demethylation in human liver microsomes (HLMs) genotyped for CYP2C8*3, in CYP2C8*3/*3 pooled HLMs
Yuji Mukai et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1137, 121928-121928 (2019-12-27)
Therapeutic drug monitoring is important in patients taking BCR-ABL and Bruton's tyrosine kinase inhibitors (TKIs). Some TKI active metabolites with long elimination half-lives, such as dihydrodiol ibrutinib (DHI), N-desmethyl imatinib (N-DI), and N-desmethyl ponatinib (N-DP), have been characterized, indicating that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service